Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Implements New Drug Innovation And Production Project

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Science and Technology has officially started implementing the new drug innovation and production project to become a pharmaceutical powerhouse (PharmAsia News, Sept. 8, 2008). The country's program with the highest investment, has allocated RMB 5.3 billion ($775 million) for a total of 970 research topics. The first batch of 121 topics with funding of RMB 1 billion has commenced. The second batch of 849 topics which will use the remaining funds has been identified and are ready to go. Sang Guo-wei, chief technology director for the program, stated that chemical drugs will be the emphasis, biopharmaceutical products the highlight and TCM the unique feature. (Click here for more - Chinese language)

You may also be interested in...

Shanghai Institute of Materia Medica Successfully Develops China’s First Quinolone Drug

Shanghai Institute of Materia Medica has successfully developed China's first quinolone drug - antofloxacin hydrochloride - with intellectual property rights. This represents an achievement under the country's new drug innovation and production program (PharmAsia News, May 11, 2009). With a decade's research and three phases of clinical trials, the drug has gained China's rare Class-I new drug certification and is ready to market. Compared to recent fourth-generation generic quinolone drugs such as prulifloxacin, gemifloxacin and moxifloxacin, the new drug demonstrates advantages in its metabolic characteristics and production costs. It offers long-acting effectiveness of up to 95 percent with the lowest oral dosage for respiratory, urinary and skin infections, making it affordable to the general public. Moreover, its phototoxicity is markedly lower than current similar products including lomefloxacin, sparfloxacin, fleroxacin and ciprofloxacin. (Click here for more - Chinese Language)

China Kicks Off Pharmaceutical Manufacturing And Innovation Project

A task force comprising members from China's Ministry of Health and 10 governmental bodies has proposed pharmaceutical manufacturing and innovation guidelines under the national science and technology development program. The project has two key targets, first of which is the development of a batch of medical products that are safe, efficient, convenient and cheap to prevent and treat major diseases. The second is the development of innovative drugs with intellectual property rights and market competitiveness, building up of advanced technology platforms, as well as shaping new drug creativity and technology systems to support the nation's pharmaceutical innovation. (Click here for more - Chinese Language)

Innovative Trial Designs Are 'Life And Death Matter' For Pharma, Amgen Tells US FDA

Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts